About Sloning BioTechnology
Sloning BioTechnology is a company based in Puchheim (Germany) founded in 2001 was acquired by MorphoSys in October 2010. Sloning BioTechnology has raised $11.86 million across 3 funding rounds from investors including MorphoSys, KfW and HBM Healthcare Investments. Sloning BioTechnology operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Puchheim, Germany
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Sloning BioTechnology
Sloning BioTechnology has successfully raised a total of $11.86M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sloning BioTechnology
Sloning BioTechnology has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include MorphoSys, KfW and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked | |
|
Early-stage VC firm investing in smart & deep-tech, fin-tech and life science & health-tech sectors
|
Locked | Locked | Locked | |
|
Investments in asset management and fintech are made by DEWB.
|
Locked | Locked | Locked |
Investor details for Sloning BioTechnology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sloning BioTechnology
Investment portfolio details for Sloning BioTechnology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Sloning BioTechnology
Detailed financials for Sloning BioTechnology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sloning Biotechnology Comparisons
Peer comparison for Sloning BioTechnology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sloning BioTechnology
Sloning BioTechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Sloning BioTechnology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sloning Biotechnology
Complete news archive for Sloning BioTechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sloning BioTechnology
Sloning BioTechnology was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Sloning BioTechnology is headquartered in Puchheim, Germany. It is registered at Puchheim, Bavaria, Germany.
Sloning BioTechnology is a funded company, having raised a total of $11.86M across 3 funding rounds to date.
Sloning Biotechnology has developed a patented technology platform to build protein libraries. Its patented Slonomics technology enables the precise construction of protein libraries comprising defined mixtures of amino acids at predetermined positions with speed. It claims that the technology opens the way to a new and flexible approach to generating optimized proteins, such as antibodies. In October 2010, it was acquired by MorphoSys.
Sloning BioTechnology's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Sloning BioTechnology has 5 investors. Key investors include MorphoSys, KfW, HBM Healthcare Investments, LBBW Venture Capital, and DEWB.